# Torax Medical

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/torax-medical

- Industry: Medical Devices & Equipment
- Headquarters: Shoreview, US
- Website: www.toraxmedical.com
- Total disclosed funding: $70M
- Latest round: Series E (Aug 4, 2016)
- Investors on record: 7

## About

Torax Medical, Inc. develops medical devices focused on treating gastroesophageal reflux disease (GERD) through innovative solutions like the LINX™ Reflux Management System, which improves patient outcomes post-surgery.Founded in 2002 and headquartered in Shoreview, US, Torax Medical, Inc. specializes in developing devices for GERD treatment. In February 2017, the company was acquired by Ethicon, Inc. in a deal that closed in March 2017. The founder's history is not publicly detailed, and there are no mentions of the company having subsidiaries. Torax Medical has engaged in 9 deals since its inception, with its most recent funding round being Series E in February 2017, which raised USD 25.00 mn led by Johnson & Johnson Innovation. The total amount raised by the company amounts to USD 25.00 mn.Torax Medical, Inc. offers the LINX™ Reflux Management System, a device designed for the treatment of gastroesophageal reflux disease (GERD). The LINX system features a flexible ring of small magnets that is laparoscopically implanted around the lower esophageal sphincter (LES), helping to prevent acid reflux while allowing natural bodily functions like belching. It caters to patients who do not find relief with proton pump inhibitors and those with Barrett’s Esophagus, and is available in the U.S. and other international markets.Torax Medical, Inc. generates revenue primarily through sales of the LINX™ Reflux Management System to healthcare providers and institutions. The revenue model focuses on direct business-to-business transactions with hospitals and surgical centers, emphasizing the product's advanced technology and clinical benefits. As of now, over 50,000 LINX devices have been sold globally, indicating a solid footprint in the market for GERD treatment.Looking forward, Torax Medical, Inc. aims to enhance its product offerings and expand its market reach. The company is expected to launch new products designed to improve GERD treatment options over the next few years. Plans for market expansion include targeting additional geographic regions, though specific regions and timelines have not been disclosed. The recent funding from the Series E round will likely support these initiatives, particularly in product development and market penetration strategies, following the acquisition by Ethicon, Inc. in March 2017.

## Funding rounds

- Series E, Aug 4, 2016, $25M — Mayo Clinic Ventures, Sanderling Ventures, Thomas, McNerney & Partners, Accuitive Medical Ventures, Johnson & Johnson Innovation, Piper Sandler, Kaiser Permanente Ventures
- Series D, Sep 14, 2012, $16M — Mayo Clinic Ventures, Sanderling Ventures, Thomas, McNerney & Partners, Accuitive Medical Ventures, Piper Sandler, Kaiser Permanente Ventures
- Series C, Apr 23, 2009, $15M — Mayo Clinic Ventures, Sanderling Ventures, Thomas, McNerney & Partners, Accuitive Medical Ventures
- Series B, Jun 28, 2005, $10M — Mayo Clinic Ventures, Sanderling Ventures, Thomas, McNerney & Partners
- Series A, Jun 1, 2004, $3.4M — Mayo Clinic Ventures, Sanderling Ventures

## Investors

- Mayo Clinic Ventures (https://capitalatlas.ai/funds/mayo-clinic-ventures) — Series A, Series B, Series C, Series D, Series E
- Sanderling Ventures (https://capitalatlas.ai/funds/sanderling-ventures) — Series A, Series B, Series C, Series D, Series E
- Thomas, McNerney & Partners (https://capitalatlas.ai/funds/thomas-mcnerney-partners) — Series B, Series C, Series D, Series E
- Accuitive Medical Ventures (https://capitalatlas.ai/funds/accuitive-medical-ventures) — Series C, Series D, Series E
- Piper Sandler (https://capitalatlas.ai/funds/piper-sandler) — Series D, Series E
- Kaiser Permanente Ventures (https://capitalatlas.ai/funds/kaiser-permanente-ventures) — Series D, Series E
- Johnson & Johnson Innovation (https://capitalatlas.ai/funds/johnson-johnson-innovation) — Series E